Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.

Authors :: Kolkailah, Ahmed A.
Wiviott, Stephen D.
Raz, Itamar
Murphy, Sabina A.
Mosenzon, Ofri
Bhatt, Deepak L.
Leiter, Lawrence A.
Wilding, John P. H.
Gause-Nilsson, Ingrid
Sabatine, Marc S.
McGuire, Darren K.
Source :: Diabetes Care; Feb2022, Vol. 45 Issue 2, pe27-e29, 3p
Publication Year :: 2022
Abstract: The article presents the discussion on the effect of Dapagliflozin on Hematocrit in patients with type 2 diabetes at high cardiovascular risk. Topics include expanding beyond patients with type 2 diabetes (T2D) to patients with heart failure and chronic kidney disease regardless of T2D status; and evidence suggesting a relationship between SGLT2 inhibitors and increasing hematocrit (Hct) hemoglobiin.

Subjects :: DAPAGLIFLOZIN
HEART valve prosthesis implantation
TYPE 2 diabetes
EMPAGLIFLOZIN
CARDIOVASCULAR diseases risk factors
HEMATOCRIT
MEDICAL research

Full Text Access

Tools